Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease-Reference-Cited by-同舟云学术

Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease

Published:2018-02-23 Issue:2 Volume:104 Page:282-289
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Schuck Robert N.¹,Woodcock Janet²,Zineh Issam¹,Stein Peter³,Jarow Jonathan²,Temple Robert²,Permutt Thomas⁴,LaVange Lisa⁴,Beaver Julia A.³,Charlab Rosane¹,Blumenthal Gideon M.³,Dorff Sarah E.¹,Leptak Christopher³,Lemery Steven³,Rogers Hobart¹,Chowdhury Badrul³,Litwack E. David⁵,Pacanowski Michael¹

Affiliation:

1. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Silver Spring Maryland USA

2. Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Silver Spring Maryland USA

3. Office of New Drugs, Center for Drug Evaluation and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Silver Spring Maryland USA

4. Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Silver Spring Maryland USA

5. Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration; Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.1041/fullpdf

Reference29 articles.

1. U.S. Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labeling http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm 2017

2. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the united states food and drug administration;Zineh;Pharmacotherapy,2011

3. Leveraging genomic factors to improve benefit-risk;Schuck;Clin. Transl. Sci.,2017

4. Next-generation medicines: past regulatory experience and considerations for the future;Pacanowski;Clin. Pharmacol. Ther.,2014

5. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation;Zineh;Clin. Pharmacol. Ther.,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance;BMJ Open;2022-07

2. Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvals;Pharmacogenomics;2022-05

3. Biomarkers in drug development;Atkinson's Principles of Clinical Pharmacology;2022

4. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases;Orphanet Journal of Rare Diseases;2021-06-09

5. The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue;Journal of Biological Chemistry;2021-01